Richard D. Carvajal

TL;DR: A four-part phase 1/2, first-in-human study has been initiated that evaluates BDC-1001 with or without (±) an immune checkpoint inhibitor targeting PD-1 in patients with HER2-expressing or Her2-amplified advanced/metastatic solid tumors.

TL;DR: Ipilimumab is the first immunotherapy approved by the FDA for patients with advanced melanoma based on the overall survival benefit in a phase III setting, and represents a paradigm shift in melanoma management with its success promoting the evaluation of monoclonal antibodies targeted against a number of other regulatory checkpoints in patients withAdvanced melanoma.

TL;DR: In this paper , the authors evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the oral protein kinase C inhibitor LXS196 in 68 patients with uveal melanoma.

TL;DR: S+D can stabilize disease in up to 29% of pts with these subtypes, especially SS and LMS, and CBR appears to be promising.

TL;DR: This data indicates that NGS panels used in this study have the potential to provide real-time information about the status of individual cells and thereby improve the prognosis for individual patients and improve the quality of care.